JournalTOCs

Antiviral Chemistry and Chemotherapy
Journal Prestige (SJR): 0.635

Citation Impact (citeScore): 2
Number of Followers: 1

This is an Open Access Journal

Open Access journal
ISSN (Print) 0956-3202 - ISSN (Online) 2040-2066
Published by Sage Publications

[1176 journals]

The continuing need for therapeutic agents for respiratory syncytial virus
infection
- Authors: Norbert J Roberts
  Abstract: Antiviral Chemistry and Chemotherapy, Volume 31, Issue , January-December 2023.
  Respiratory syncytial virus infections recur throughout life despite induction of immunity by the first natural infection. An effective vaccine has long been sought but no vaccine is currently licensed, although promising candidates are currently being developed based on greater knowledge of the virus properties. However, there are significant populations that may not be protected adequately by a vaccine or are unable to be vaccinated. Thus, there is a continued need for effective therapeutic agents to treat the infection, especially in higher-risk individuals, a perspective presented in this article.
  Citation: Antiviral Chemistry and Chemotherapy
  PubDate: 2023-08-14T05:00:14Z
  DOI: 10.1177/20402066231194424
  Issue No: Vol. 31 (2023)
The development of BVDU: An odyssey
- Authors: Erik De Clercq
  Abstract: Antiviral Chemistry and Chemotherapy, Volume 31, Issue , January-December 2023.
  Brivudin, ((E)-5-(2-bromovinyl)-2’-deoxyuridine (BVDU) can be considered the gold standard for the treatment of varicella-zoster virus (VZV) infections, such as herpes zoster (shingles). It is available for clinical use in most European countries (except for the UK) and over the whole world (except for the US and Canada). Besides VZV its activity spectrum also includes various other herpesviruses, such as herpes simplex virus type 1 (HSV-1). Its activity against VZV and HSV-1 depends on phosphorylation by the virus-encoded thymidine kinase (TK). In its active form (BVDU TP or BVDU 5’-triphosphate), it can act as both substrate and inhibitor of the viral (i.e., HSV-1) DNA polymerase. It has proven to be effective against herpes zoster, including post-herpetic neuralgia (PHN). It is contra-indicated in patients concomitantly treated by 5-fluorouracil (FU), since its degradation product, (E)-5-(2-bromovinyl)uracil, is inhibitory to the catabolism of FU, which may enhance the toxicity of the latter. A new compound, the bicyclic nucleoside analogue (BCNA) Cf-1743, has been described, which is a more potent inhibitor of VZV replication than BVDU and which does not interfere with the catabolism of FU. It is applicable orally, as its 5’-valine ester FV-100 (Fermavir), but has not (yet) been marketed for clinical use.
  Citation: Antiviral Chemistry and Chemotherapy
  PubDate: 2023-01-30T06:38:26Z
  DOI: 10.1177/20402066231152971
  Issue No: Vol. 31 (2023)

HOME > Browse the 73 Subjects covered by JournalTOCs
Subject	Total Journals